

Clinical trials of atrasentan

TrialResults-center www.trialresultscenter.org

1 diabetic kidney disease

Trial	Treatments	Patients	Trials design and methods
atrasentan vs placebo			
SONAR <i>ongoing</i> [NCT01858532] n=4148 follow-up:	Atrasentan Oral daily low dose for 48 months. versus Placebo	subjects with type 2 diabetes and nephropathy who are treated with the maximum tolerated labeled daily dose of a Renin Angiotensin System inhibitor	

More details and results :

- All mechanism for diabetic kidney disease in all type of patients at <http://www.trialresultscenter.org/go-Q667>

References

SONAR, 0:

ongoing trial NCT01858532